Lupin signs exclusive distribution pact with ForDoz Pharma for 2 Complex Injectable Assets

▴ lupin-signs-exclusive-distribution-pact-with-fordoz-pharma
The assets will be manufactured in ForDoz’s U.S. based manufacturing site

Pharma major Lupin Limited (Lupin) announced today that its U.S. based wholly-owned subsidiary Lupin Inc. has entered into an agreement with ForDoz Pharma Corp (ForDoz) for granting Lupin the exclusive rights to market and distribute 2 complex injectable assets in advanced stages of development in the U.S. and its territories.

The two assets are in the Oncology and Anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals.

The assets will be manufactured in ForDoz’s U.S. based manufacturing site and ForDoz will be responsible for the development and obtaining the necessary regulatory approvals. Lupin shall leverage its existing commercial infrastructure for marketing and distribution of the two assets.

Commenting on the development Alok Sonig, CEO, US Generics and Global Head, Generics R&D and Biosimilars for Lupin said, “The partnered assets are a key, strategic addition to our complex injectables pipeline and will bolster our Institutional business offering. These assets will complement Lupin’s ongoing organic R&D efforts in complex assets including inhalation and long-acting injectables as well as Biosimilars.”

According to James He, Founder and CEO of ForDoz Pharma Corp, “ForDoz Pharma is excited to partner our complex injectable flagship products with Lupin. Lupin’s leadership presence in the U.S. will complement ForDoz’s scientific and complex injectable manufacturing capability to bring affordable medicines to patients in an efficient manner”.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Tags : #LupinInc #FordozPhrama #USFDAApprovals #Oncology #AntiInfective #LatestPharmaNewsAug6

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Serum Institute of India Partners with Oxford University to Develop Meningitis-B VaccineApril 18, 2024
Ethical Concerns Arise: Nestlé Accused of Adding Sugar and Honey to Infant Formula and Breakfast Cereals in Low-Income CountriesApril 18, 2024
Empowering India's Youth: IG Drones & AASSC Launch Drone Skill Program, to Upskill 10M YouthApril 17, 2024
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment TechnologyApril 17, 2024
Top 5 online learning platform for learnersApril 17, 2024
Broad-Spectrum RNA Vaccine Breakthrough for Enhanced Virus ProtectionApril 17, 2024
The Impact of Excessive Internet Usage on School Absence: Finnish Study Reveals Key FindingsApril 17, 2024
Uncovering Delhi's Illegal Fertility Centre Operations: Insights from Recent Child Trafficking CasesApril 17, 2024
CarDekho's CSR Arm Girnar Foundation Hosts Health Check-up Camps for Underprivileged Children in Jaipur and GurugramApril 16, 2024
Atal Incubation Centre – Centre for Cellular and Molecular Biology (AIC-CCMB) signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India April 16, 2024
AVEKSHA, four-day care centres, for the kids of industrial workers inauguratedApril 16, 2024
Nearly a third of the constituencies have zero women candidates in Phase 1 and 2 of LS Elections; reveals The Quantum Hub’s Factsheet April 16, 2024
Emergency Healthcare Provider Medulance Secures $3 Million Series A Funding Led by Alkemi Growth CapitalApril 16, 2024
The Healing Power of Natural Diversity: How Nature Boosts Mental HealthApril 16, 2024
Unveiling Cellular Recycling: How Nutrient-Starved Cells Adapt to Stressful ConditionsApril 16, 2024
Advancing Cancer Care: AIIMS Bhopal’s Workshop on Biomarker Interpretation in Breast CancerApril 15, 2024
10 Powerful Benefits to Diversify Healthcare Advertising ChannelsApril 15, 2024
Understanding Hospital Sink Contamination: Challenges in Fighting Multidrug-Resistant BacteriaApril 15, 2024
Rajasthan’s Swine Flu Situation: Health Department Observes DeclineApril 15, 2024
Is Your Doctor’s Prescription Incomplete ? Insights from Recent ICMR Study Suggests So!April 13, 2024